NBY vs PCYO vs MSEX vs AYTU vs AWR

For growth investors, American States Water Company (AWR) is the stronger pick with 10.

5% revenue growth year-over-year, versus -9. 3% for Pure Cycle Corporation (PCYO). Pure Cycle Corporation (PCYO) offers the better valuation at 21. 6x trailing P/E, making it the more compelling value choice. Analysts rate Pure Cycle Corporation (PCYO) a "Buy" — based on 1 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

On trailing P/E, Pure Cycle Corporation (PCYO) is the cheapest at 21.

6x versus American States Water Company at 22. 8x. On forward P/E, Middlesex Water Company is actually cheaper at 20. 1x — notably different from the trailing picture, reflecting expected earnings growth. The PEG ratio (P/E divided by earnings growth rate) is the most growth-adjusted single valuation metric: American States Water Company wins at 2. 70x versus Middlesex Water Company's 12. 58x.

Over the past 5 years, American States Water Company (AWR) delivered a total return of +7.

3%, compared to -99. 9% for NovaBay Pharmaceuticals, Inc. (NBY). Over 10 years, the gap is even starker: PCYO returned +159. 6% versus AYTU's -100. 0%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

By beta (market sensitivity over 5 years), American States Water Company (AWR) is the lower-risk stock at -0.

17β versus NovaBay Pharmaceuticals, Inc. 's 2. 43β — meaning NBY is approximately -1513% more volatile than AWR relative to the S&P 500. On balance sheet safety, Pure Cycle Corporation (PCYO) carries a lower debt/equity ratio of 5% versus 121% for Aytu BioPharma, Inc. — giving it more financial flexibility in a downturn.

By revenue growth (latest reported year), American States Water Company (AWR) is pulling ahead at 10.

5% versus -9. 3% for Pure Cycle Corporation (PCYO). On earnings-per-share growth, the picture is similar: NovaBay Pharmaceuticals, Inc. grew EPS 98. 2% year-over-year, compared to -4. 5% for Middlesex Water Company. Over a 3-year CAGR, AWR leads at 10. 2% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

Pure Cycle Corporation (PCYO) is the more profitable company, earning 50.

3% net margin versus -73. 8% for NovaBay Pharmaceuticals, Inc. — meaning it keeps 50. 3% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: AWR leads at 30. 9% versus -59. 7% for NBY. At the gross margin level — before operating expenses — AYTU leads at 69. 0%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

The PEG ratio (forward P/E divided by expected earnings growth rate) is the most precise measure of undervaluation relative to growth potential.

By this metric, American States Water Company (AWR) is the more undervalued stock at a PEG of 2. 70x versus Middlesex Water Company's 12. 58x. Both stocks trade at elevated growth-adjusted valuations, so expected growth needs to materialise. On forward earnings alone, Middlesex Water Company (MSEX) trades at 20. 1x forward P/E versus 20. 7x for American States Water Company — 0. 6x cheaper on a one-year earnings basis. Analyst consensus price targets imply the most upside for AWR: 16. 5% to $89. 50.

In this comparison, MSEX (2.

7% yield), AWR (2. 5% yield) pay a dividend. NBY, PCYO, AYTU do not pay a meaningful dividend and should not be held primarily for income.

For long-horizon retirement investors, American States Water Company (AWR) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β -0.

17), 2. 5% yield, +123. 2% 10Y return). NovaBay Pharmaceuticals, Inc. (NBY) carries a higher beta of 2. 43 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (AWR: +123. 2%, NBY: -100. 0%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

These companies operate in different sectors (NBY (Healthcare) and PCYO (Utilities) and MSEX (Utilities) and AYTU (Healthcare) and AWR (Utilities)), which means they face different economic cycles, regulatory environments, and macro sensitivities — making direct comparison nuanced.

MSEX, AWR pay a dividend while NBY, PCYO, AYTU do not, making them suitable for different income and tax situations. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.